Intestinal microbiota: A regulator of intestinal inflammation and cardiac ischemia?

Current Drug Targets

Volumn 16, Issue 3, 2015, Pages 199-208

  Bashashati, Mohammad ^a,b   Habibi, Hamid R ^a   Keshavarzian, Ali ^c,d   Schmulson, Max ^e   Sharkey, Keith A ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b Paul L Foster School of Medicine   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d UTRECHT UNIVERSITY   (Netherlands)

^e UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Coronary artery disease; Gastrointestinal inflammation; Inflammatory bowel disease; Microbiota; Trimethylamine Noxide

Indexed keywords

CHOLINE; PREBIOTIC AGENT; PROBIOTIC AGENT; TRIMETHYLAMINE OXIDE;

ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; DIGESTIVE SYSTEM INFLAMMATION; ENTERITIS; ENVIRONMENTAL FACTOR; ESCHERICHIA COLI; FAECALIBACTERIUM PRAUSNITZII; HEART MUSCLE ISCHEMIA; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; METABOLOMICS; MYCOBACTERIUM AVIUM SUBSP. PARATUBERCULOSIS; NONHUMAN; UVEITIS; VASCULITIS; ANIMAL; HUMAN; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; MICROBIOLOGY; MYOCARDIAL ISCHEMIA; PHYSIOLOGY;

ANIMALS; GASTROINTESTINAL MICROBIOME; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; MYOCARDIAL ISCHEMIA;

EID: 84930976812     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450116666150120104012     Document Type: Article

References (109)

1. [1] Danese S, Sans M, Fiocchi C. Inflammatory bowel disease: the role of environmental factors. Autoimmun Rev 2004; 3: 394-400.
2. [2] Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142: 46-54.
3. [3] Shanahan F. The microbiota in inflammatory bowel disease: friend, bystander, and sometime-villain. Nutr Rev 2012; 70 Suppl 1: S31-S37.
4. [4] Kostic AD, Xavier RJ, Gevers D. The Microbiome in Inflammatory Bowel Disease: Current Status and the Future Ahead. Gastroenterology 2014; 146: 1489-99.
5. [5] Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007; 369: 1641-57.
6. [6] Ott C, Scholmerich J. Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol 2013; 10: 585-95.
7. [7] Tigas S, Tsatsoulis A. Endocrine and metabolic manifestations in inflammatory bowel disease. Ann Gastroenterol 2012; 25: 37-44.
8. [8] Tan VP, Chung A, Yan BP, Gibson PR. Venous and arterial disease in inflammatory bowel disease. J Gastroenterol Hepatol 2013; 28: 1095-113.
9. [9] Fumery M, Xiaocang C, Dauchet L, et al. Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: A meta-analysis of observational studies. J Crohns Colitis 2013; 8: 469-79.
10. [10] Daryani NE, Habibi AN, Bashashati M, et al. Takayasu's arteritis associated with Crohn's disease: a case report. J Med Case Rep 2008; 2: 87.
11. [11] Kruschewski M, Buhr HJ. The vasculitis in IBD is associated with the degree of inflammation. Dig Dis Sci 2010; 55: 733-8.
12. [12] Yarur AJ, Deshpande AR, Pechman DM, et al. Inflammatory bowel disease is associated with an increased incidence of cardiovascular events. Am J Gastroenterol 2011; 106: 741-7.
13. [13] Haapamaki J, Roine RP, Turunen U, Farkkila MA, Arkkila PE. Increased risk for coronary heart disease, asthma, and connective tissue diseases in inflammatory bowel disease. J Crohns Colitis 2011; 5: 41-7.
14. [14] Gandhi S, Narula N, Marshall JK, Farkouh M. Are patients with inflammatory bowel disease at increased risk of coronary artery disease? Am J Med 2012; 125: 956-62.
15. [15] Singh S, Singh H, Loftus EV, Jr., Pardi DS. Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2014; 12: 382-93.
16. [16] Yousuf O, Mohanty BD, Martin SS, et al. High-sensitivity Creactive protein and cardiovascular disease: a resolute belief or an elusive link? J Am Coll Cardiol 2013; 62: 397-408.
17. [17] Hartman J, Frishman WH. Inflammation and atherosclerosis: a review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy. Cardiol Rev 2014; 22: 147-51.
18. [18] Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.
19. [19] Laugerette F, Vors C, Peretti N, Michalski MC. Complex links between dietary lipids, endogenous endotoxins and metabolic inflammation. Biochimie 2011; 93: 39-45.
20. [20] Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002; 122: 44-54.
21. [21] Cao Y, Shen J, Ran ZH. Association between Faecalibacterium prausnitzii Reduction and Inflammatory Bowel Disease: A Meta-Analysis and Systematic Review of the Literature. Gastroenterol Res Pract 2014; 2014: 872725.
22. [22] Darfeuille-Michaud A, Boudeau J, Bulois P, et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 2004; 127: 412-21.
23. [23] Frank DN, St Amand AL, Feldman RA, et al. Molecularphylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA 2007; 104: 13780-5.
24. [24] Ott SJ, Musfeldt M, Wenderoth DF, et al. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut 2004; 53: 685-93.
25. [25] Manichanh C, Borruel N, Casellas F, Guarner F. The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol 2012; 9: 599-608.
26. [26] Lockhart PB, Bolger AF, Papapanou PN, et al. Periodontal disease and atherosclerotic vascular disease: does the evidence support an independent association?: a scientific statement from the American Heart Association. Circulation 2012; 125: 2520-44.
27. [27] Nonnenmacher C, Stelzel M, Susin C, et al. Periodontal microbiota in patients with coronary artery disease measured by real-time polymerase chain reaction: a case-control study. J Periodontol 2007; 78: 1724-30.
28. [28] Said HS, Suda W, Nakagome S, et al. Dysbiosis of salivary microbiota in inflammatory bowel disease and its association with oral immunological biomarkers. DNA Res 2014; 21: 15-25.
29. [29] De Preter V, Verbeke K. Metabolomics as a diagnostic tool in gastroenterology. World J Gastrointest Pharmacol Ther 2013; 4: 97-107.
30. [30] Storr M, Vogel HJ, Schicho R. Metabolomics: is it useful for inflammatory bowel diseases? Curr Opin Gastroenterol 2013; 29: 378-83.
31. [31] Le Gall G, Noor SO, Ridgway K, et al. Metabolomics of fecal extracts detects altered metabolic activity of gut microbiota in ulcerative colitis and irritable bowel syndrome. J Proteome Res 2011; 10: 4208-18.
32. [32] Schicho R, Shaykhutdinov R, Ngo J, et al. Quantitative metabolomic profiling of serum, plasma, and urine by (1)H NMR spectroscopy discriminates between patients with inflammatory bowel disease and healthy individuals. J Proteome Res 2012; 11: 3344-57.
33. [33] Tang WH, Wang Z, Levison BS, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 2013; 368: 1575-84.
34. [34] Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011; 472: 57-63.
35. [35] Koeth RA, Wang Z, Levison BS, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 2013; 19: 576-85.
36. [36] Jess T, Gamborg M, Munkholm P, Sorensen TI. Overall and causespecific mortality in ulcerative colitis: meta-analysis of populationbased inception cohort studies. Am J Gastroenterol 2007; 102: 609-17.
37. [37] Duricova D, Pedersen N, Elkjaer M, et al. Overall and causespecific mortality in Crohn's disease: a meta-analysis of populationbased studies. Inflamm Bowel Dis 2010; 16: 347-53.
38. [38] Manninen P, Karvonen AL, Huhtala H, et al. Mortality in ulcerative colitis and Crohn's disease. A population-based study in Finland. J Crohns Colitis 2012; 6: 524-8.
39. [39] Kristensen SL, Ahlehoff O, Lindhardsen J, et al. Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death--a Danish nationwide cohort study. PLoS One 2013; 8: e56944.
40. [40] Rungoe C, Basit S, Ranthe MF, et al. Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study. Gut 2013; 62: 689-94.
41. [41] Bernstein CN, Wajda A, Blanchard JF. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study. Clin Gastroenterol Hepatol 2008; 6: 41-5.
42. [42] Andersohn F, Waring M, Garbe E. Risk of ischemic stroke in patients with Crohn's disease: a population-based nested case-control study. Inflamm Bowel Dis 2010; 16: 1387-92.
43. [43] Holdt LM, Teupser D. Recent studies of the human chromosome 9p21 locus, which is associated with atherosclerosis in human populations. Arterioscler Thromb Vasc Biol 2012; 32: 196-206.
44. [44] Beckie TM, Beckstead JW, Groer MW. The association between variants on chromosome 9p21 and inflammatory biomarkers in ethnically diverse women with coronary heart disease: a pilot study. Biol Res Nurs 2011; 13: 306-19.
45. [45] Martin TM, Zhang G, Luo J, et al. A locus on chromosome 9p predisposes to a specific disease manifestation, acute anterior uveitis, in ankylosing spondylitis, a genetically complex, multisystem, inflammatory disease. Arthritis Rheum 2005; 52: 269-74.
46. [46] Sayols-Baixeras S, Lluis-Ganella C, Lucas G, Elosua R. Pathogenesis of coronary artery disease: focus on genetic risk factors and identification of genetic variants. Appl Clin Genet 2014; 7: 15-32.
47. [47] Deloukas P, Kanoni S, Willenborg C, et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet 2013; 45: 25-33.
48. [48] Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012; 491: 119-24.
49. [49] Spina L, Saibeni S, Battaglioli T, et al. Thrombosis in inflammatory bowel diseases: role of inherited thrombophilia. Am J Gastroenterol 2005; 100: 2036-41.
50. [50] Papa A, De S, V, Gasbarrini A, et al. Prevalence of factor V Leiden and the G20210A prothrombin-gene mutation in inflammatory bowel disease. Blood Coagul Fibrinolysis 2000; 11: 499-503.
51. [51] Kader HA, Berman WF, Al-Seraihy AS, et al. Prevalence of factor V G1691A (Leiden), prothrombin G20210A, and methylene tetrahydrofolate reductase C677T thrombophilic mutations in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2002; 35: 629-35.
52. [52] Yasa MH, Bolaman Z, Yukselen V, et al. Factor V Leiden G1691A, prothrombin G20210A, and MTHFR C677T mutations in Turkish inflammatory bowel disease patients. Hepatogastroenterology 2007; 54: 1438-42.
53. [53] Farzadfar F, Finucane MM, Danaei G, et al. National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3.0 million participants. Lancet 2011; 377: 578-86.
54. [54] Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med 2007; 356: 2388-98.
55. [55] Sappati Biyyani RS, Fahmy NM, Baum E, Nelson KM, King JF. Inflammatory bowel disease and coronary artery disease. Indian J Gastroenterol 2009; 28: 28-30.
56. [56] Akhabue E, Thiboutot J, Cheng JW, et al. New and emerging risk factors for coronary heart disease. Am J Med Sci 2014; 347: 151-8.
57. [57] Oussalah A, Gueant JL, Peyrin-Biroulet L. Meta-analysis: hyperhomocysteinaemia in inflammatory bowel diseases. Aliment Pharmacol Ther 2011; 34: 1173-84.
58. [58] Saibeni S, Cattaneo M, Vecchi M, et al. Low vitamin B(6) plasma levels, a risk factor for thrombosis, in inflammatory bowel disease: role of inflammation and correlation with acute phase reactants. Am J Gastroenterol 2003; 98: 112-7.
59. [59] Mullin GE. Micronutrients and inflammatory bowel disease. Nutr Clin Pract 2012; 27: 136-7.
60. [60] Backhed F. Programming of host metabolism by the gut microbiota. Ann Nutr Metab 2011; 58 Suppl 2: 44-52.
61. [61] Hollister EB, Gao C, Versalovic J. Compositional and functional features of the gastrointestinal microbiome and their effects on human health. Gastroenterology 2014; 146: 1449-58.
62. [62] Xu J, Gordon JI. Honor thy symbionts. Proc Natl Acad Sci USA 2003; 100: 10452-9.
63. [63] Power SE, O'Toole PW, Stanton C, Ross RP, Fitzgerald GF. Intestinal microbiota, diet and health. Br J Nutr 2014; 111: 387-402.
64. [64] Koren O, Knights D, Gonzalez A, et al. A guide to enterotypes across the human body: meta-analysis of microbial community structures in human microbiome datasets. PLoS Comput Biol 2013; 9: e1002863.
65. [65] Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature 2011; 473: 174-80.
66. [66] Dewhirst FE, Chen T, Izard J, et al. The human oral microbiome. J Bacteriol 2010; 192: 5002-17.
67. [67] Wade WG. The oral microbiome in health and disease. Pharmacol Res 2013; 69: 137-43.
68. [68] Marcobal A, Kashyap PC, Nelson TA, et al. A metabolomic view of how the human gut microbiota impacts the host metabolome using humanized and gnotobiotic mice. ISME J 2013; 7: 1933-43.
69. [69] Jacobs DM, Gaudier E, van DJ, Vaughan EE. Non-digestible food ingredients, colonic microbiota and the impact on gut health and immunity: a role for metabolomics. Curr Drug Metab 2009; 10: 41-54.
70. [70] Wrzosek L, Miquel S, Noordine ML, et al. Bacteroides thetaiotaomicron and Faecalibacterium prausnitzii influence the production of mucus glycans and the development of goblet cells in the colonic epithelium of a gnotobiotic model rodent. BMC Biol 2013; 11: 61.
71. [71] Brito F, Zaltman C, Carvalho AT, et al. Subgingival microflora in inflammatory bowel disease patients with untreated periodontitis. Eur J Gastroenterol Hepatol 2013; 25: 239-45.
72. Demmer RT, Desvarieux M. Periodontal infections and cardiovascular disease: the heart of the matter. J Am Dent Assoc 2006; 137 Suppl: 14S-20S.
73. [73] Koren O, Spor A, Felin J, et al. Human oral, gut, and plaque microbiota in patients with atherosclerosis. Proc Natl Acad Sci USA 2011; 108 Suppl 1: 4592-8.
74. [74] Karlsson FH, Fak F, Nookaew I, et al. Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat Commun 2012; 3: 1245.
75. [75] Hezel M, Weitzberg E. The oral microbiome and nitric oxide homoeostasis. Oral Dis 2015; 21: 7-16.
76. [76] Caesar R, Fak F, Backhed F. Effects of gut microbiota on obesity and atherosclerosis via modulation of inflammation and lipid metabolism. J Intern Med 2010; 268: 320-28.
77. [77] Karlsson F, Tremaroli V, Nielsen J, Backhed F. Assessing the human gut microbiota in metabolic diseases. Diabetes 2013; 62: 3341-9.
78. [78] Le Chatelier E, Nielsen T, Qin J, et al. Richness of human gut microbiome correlates with metabolic markers. Nature 2013; 500: 541-6.
79. [79] Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006; 444: 1022-3.
80. [80] Bervoets L, Van HK, Kortleven I, et al. Differences in gut microbiota composition between obese and lean children: a crosssectional study. Gut Pathog 2013; 5: 10.
81. [81] Fink C, Karagiannides I, Bakirtzi K, Pothoulakis C. Adipose tissue and inflammatory bowel disease pathogenesis. Inflamm Bowel Dis 2012; 18: 1550-7.
82. [82] Zulian A, Cancello R, Micheletto G, et al. Visceral adipocytes: old actors in obesity and new protagonists in Crohn's disease? Gut 2012; 61: 86-94.
83. [83] Peyrin-Biroulet L, Gonzalez F, Dubuquoy L, et al. Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease. Gut 2012; 61: 78-85.
84. [84] Hou JK, Abraham B, El-Serag H. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. Am J Gastroenterol 2011; 106: 563-73.
85. [85] Alpert JS. Cardiology patient page. Nutritional advice for the patient with heart disease: what diet should we recommend for our patients? Circulation 2011; 124: e258-60.
86. [86] Bhupathiraju SN, Tucker KL. Coronary heart disease prevention: nutrients, foods, and dietary patterns. Clin Chim Acta 2011; 412: 1493-514.
87. [87] David LA, Maurice CF, Carmody RN, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014; 505: 559-63.
88. [88] Ueland PM. Choline and betaine in health and disease. J Inherit Metab Dis 2011; 34:3-15.
89. [89] Konstantinova SV, Tell GS, Vollset SE, et al. Divergent associations of plasma choline and betaine with components of metabolic syndrome in middle age and elderly men and women. J Nutr 2008; 138: 914-20.
90. [90] Dong F, Zhang L, Hao F, Tang H, Wang Y. Systemic responses of mice to dextran sulfate sodium-induced acute ulcerative colitis using 1H NMR spectroscopy. J Proteome Res 2013; 12:2958-66.
91. [91] Schicho R, Nazyrova A, Shaykhutdinov R, et al. Quantitative metabolomic profiling of serum and urine in DSS-induced ulcerative colitis of mice by (1)H NMR spectroscopy. J Proteome Res 2010; 9: 6265-73.
92. [92] Martin FP, Rezzi S, Philippe D, et al. Metabolic assessment of gradual development of moderate experimental colitis in IL-10 deficient mice. J Proteome Res 2009; 8: 2376-87.
93. [93] Murdoch TB, Fu H, MacFarlane S, et al. Urinary metabolic profiles of inflammatory bowel disease in interleukin-10 gene-deficient mice. Anal Chem 2008; 80: 5524-31.
94. [94] Caligiuri G, Rudling M, Ollivier V, et al. Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apolipoprotein E knockout mice. Mol Med 2003; 9: 10-7.
95. [95] Dawiskiba T, Deja S, Mulak A, et al. Serum and urine metabolomic fingerprinting in diagnostics of inflammatory bowel diseases. World J Gastroenterol 2014; 20: 163-74.
96. [96] Williams HR, Willsmore JD, Cox IJ, et al. Serum metabolic profiling in inflammatory bowel disease. Dig Dis Sci 2012; 57: 2157-65.
97. [97] Stephens NS, Siffledeen J, Su X, et al. Urinary NMR metabolomic profiles discriminate inflammatory bowel disease from healthy. J Crohns Colitis 2013; 7: e42-8.
98. [98] Williams HR, Cox IJ, Walker DG, et al. Characterization of inflammatory bowel disease with urinary metabolic profiling. Am J Gastroenterol 2009; 104: 1435-44.
99. [99] Roager HM, Licht TR, Poulsen SK, Larsen TM, Bahl MI. Microbial enterotypes, inferred by the prevotella-to-bacteroides ratio, remained stable during a 6-month randomized controlled diet intervention with the new nordic diet. Appl Environ Microbiol 2014; 80: 1142-9.
100. [100] Hildebrand F, Nguyen TL, Brinkman B, et al. Inflammationassociated enterotypes, host genotype, cage and inter-individual effects drive gut microbiota variation in common laboratory mice. Genome Biol 2013; 14: R4.
101. [101] Chen LL, Wang XH, Cui Y, et al. Therapeutic effects of four strains of probiotics on experimental colitis in mice. World J Gastroenterol 2009; 15: 321-7.
102. [102] O'Mahony L, Feeney M, O'Halloran S, et al. Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice. Aliment Pharmacol Ther 2001; 15: 1219-25.
103. [103] Bourreille A, Cadiot G, Le DG, et al. Saccharomyces boulardii does not prevent relapse of Crohn's disease. Clin Gastroenterol Hepatol 2013; 11: 982-7.
104. [104] Wildt S, Nordgaard I, Hansen U, Brockmann E, Rumessen JJ. A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. J Crohns Colitis 2011; 5: 115-21.
105. [105] Scaldaferri F, Gerardi V, Lopetuso LR, et al. Gut microbial flora, prebiotics, and probiotics in IBD: their current usage and utility. Biomed Res Int 2013; 2013: 435268.
106. [106] Sha S, Liang J, Chen M, et al. Systematic review: faecal microbiota transplantation therapy for digestive and nondigestive disorders in adults and children. Aliment Pharmacol Ther 2014; 39: 1003-32.
107. [107] Shanahan F, Quigley EM. Manipulation of the microbiota for treatment of IBS and IBD-challenges and controversies. Gastroenterology 2014; 146: 1554-63.
108. [108] DiRienzo DB. Effect of probiotics on biomarkers of cardiovascular disease: implications for heart-healthy diets. Nutr Rev 2014; 72: 18-29.
109. [109] Smits LP, Bouter KE, de Vos WM, Borody TJ, Nieuwdorp M. Therapeutic potential of fecal microbiota transplantation. Gastroenterology 2013; 145: 946-53.